Expert Review of Pharmacoeconomics & Outcomes Research

Article	Citations
A landscape analysis and discussion of value of gene therapies for sickle cell disease	48
Adherence to augmentation therapy for the treatment of major depressive disorder	38
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	26
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy	23
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	20
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation	20
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	18
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature	17
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	16
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	15
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	15
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	14
Social care data in the UK; current landscape, challenges, and future recommendations	13
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	13
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	12
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	12
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	11
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	11
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	10
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	10
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	10
The cost-of-illness of multiple sclerosis in Jordan	10
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	9
Addressing racial/ethnic disparities associated with Medicare Part D Star Ratings among population with Alzheimer’s disease and related dementias	9
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	9

Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review	9
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	9
How to create value with constrained budgets in oncological care? A narrative review	9
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	9
Challenges and opportunities in measuring the pediatric quality of life: exemplified by research in pediatric gastroenterology	8
The hidden burden of atopic dermatitis in central and Eastern European countries	8
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database	8
Cost-effectiveness of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing device for treatment of heavy menstrual bleeding: a systematic review	8
Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review	8
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	8
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	7
A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer	7
Evaluating the correlations of cost and utility parameters from summary statistics for probabilistic analysis in economic evaluations	7
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	7
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	7
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review	7
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	7
Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs	7
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study	7
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis	7
Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States	6
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?	6
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer	6
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	6
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	6
Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme	6
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	6
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain	6
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	6
Natural language processing – relevance to patient outcomes and real-world evidence	5
Economic benefits of global Collaborative Health technology	5
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review	5
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency	5
Not cost-effective at zero price: valuing and paying for combination therapies in cancer	5
Nonadherence to antiseizure medications: what have we learned and what can be done next?	5
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	5
Interview with Julie Frappier, health economist, and creator of the TOWWERS™ System	5
Assessing the economic impact of digital endpoints on medication adherence	5
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden	5
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	4
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	4
The utility and impact of digital endpoints for improving breast cancer outcomes	4
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	4
Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US	4
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis	4
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms	4
A visual approach to the economic evaluation of vaccines: opening the health economic black box	4
Can we achieve affordable cancer medicine prices? Developing a pathway for change	4
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	4
What to expect in 2024: important health economics and outcomes research (HEOR) trends	4

Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension	4
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study	4
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	4
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency	4
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	4
An early cost analysis of magnetic bone growth stimulation in England	4
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	4
Distinguishing features in the assessment of mHealth apps	4
How unprofessional behaviours between healthcare staff threaten patient care and safety	4
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	4
The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran	4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 2020	4
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	4
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A	4
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	4
Consumption of antidepressants and economic austerity in Brazil	3
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	3
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach	3
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	3
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	3
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	3
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	3
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	3
Economic burden of type-2 diabetes in Peru: a cost-of-illness study valuing cost differences associated with the level of glycemic control	3
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review	3
Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children	3
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil	3
Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus	3
Value attributes of advanced therapy medicinal products: a documentary analysis of comments received from stakeholders during reimbursement decisions to England’s National Institute of Health and Care	3
Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals	3
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer	3
Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument	3
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	3
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	3
Evaluation instruments for executive functions in children and adolescents: a systematic review	3
Psychometric properties of the Polish version of SF-12v2 in the general population survey	3
Health-related quality of life measured using the EQ-5D-3L: iranian population norms	3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia	3
Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review	3
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	3
Measuring valued output in primary care: challenges and reconciliation	3
An early health technology assessment of 3D anatomic models in pediatric congenital heart surgery: potential cost-effectiveness and decision uncertainty	3
Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand	2
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer	2
Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives	2
Emerging trends: the involvement of community pharmacists in the planning and execution of pharmaceutical policies and economics	2
Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis	2
The impact of under-investment on health in Southern and Central Eastern European Countries	2
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension	2
The Lebanese health economic evaluation guideline	2
Cost-utility analysis of multiple sclerosis rehabilitation in Iran	2
Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia	2
Direct medical costs of non-alcoholic fatty liver disease in Catalonia at the hospital level: a retrospective multicenter study	2
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments	2
Imputing missing patient-level data and propensity score matching in cost-effectiveness analysis in Crohn's disease	2
Prescription analysis and cost of antidepressant drugs in major depressive disorder outpatients at the tertiary care hospital of Pakistan: a prospective approach	2
Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck	2
Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada	2
Policy solutions for medication non-adherence: what can governments do?	2
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study	2
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	2
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	2
Description of characteristics, management of care and healthcare direct costs of patients with HR+/HER2- early breast cancer in Italy: a real-world study involving administrative and pathological ana	2
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies	2
Is the shift in treatment patterns towards new, more expensive drugs still driving the increase in pharmaceutical expenditure? A decomposition analysis of expenditure data in Sweden 1990–2022	2
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	2
Predictors of 30-day readmission, mortality, and length of stay for hospitalized U.S. patients with Alzheimer’s and related dementias from 2010 to 2015	2
Is Palbociclib a cost-effective strategy in the second-line treatment of metastatic breast cancer in Iran?	2
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials	2
Burden of disease and costs of infections associated with cardiac implantable electronic devices	2
Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review	2
Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country	2
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore	2
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain	2
Analysis of the prevalence of ankylosing spondylitis and treatment patterns and drug utilization among affected patients: an Italian real-world study	2
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	2
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study	2
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview	2

Cost-effectiveness analysis: fluticasone furoate/umeclidinium/vilanterol for the treatment of moderate to severe chronic obstructive pulmonary disease from the perspective of the Chilean public health	2
Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review	2
Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)	2
The impact of bone turnover marker on medication adherence and the health economics-related consequences	2
Artificial intelligence in outcomes research: a systematic scoping review	2
Canadian English translation and linguistic validation of the 13-MD to measure global health-related quality of life	2
Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma	2
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation	2
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023	2
A methodological guide for implementing and interpreting results of probabilistic analysis	2
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	2
Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step	2
Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis	2
Burden of disease of spinal muscular atrophy linked to chromosome 5q (5q-SMA) in Colombia	2
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence	2
Work productivity among patients with metastatic breast cancer in the United States	2
Mapping the schizophrenia quality of life scale to EQ-5D, HUI3 and SF-6D utility scores in patients with schizophrenia	2
Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan	2
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	2
Cost considerations of dermatological care in Jordan: a cross-sectional study	2
Effects, trends, costs associated with readmission in early-aged patients with suicidal ideation	2
Hospital incidence and costs of congenital hydrocephalus in Spain: a multicenter retrospective study	2
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach	2
The role of insurance policies in the drug pricing landscape	2
Burden of osteoarthritis in the Netherlands: a scoping review	2
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	2
Economic burden of depression in Brazil: a cost-of-illness study based on productivity losses and healthcare costs between 2010 to 2018	2
The long-term clinical impact of digital endpoints and biomarkers in data collection	2
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review	2
The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer	1
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	1
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer	1
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	1
How can environmental impacts be incorporated in health technology assessment, and how impactful would this be?	1
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders	1
Direct healthcare costs for people with cerebral palsy in the Brazilian unified health system between 2015 and 2019	1
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial	1
Letter to the editor regarding “Budget impact analysis of pneumococcal conjugate vaccines in Colombia”	1
Digital measures in epilepsy in low-resourced environments	1
A review of quality-of-life in elderly osteoarthritis	1
Budget impact analysis of pneumococcal conjugate vaccines in Colombia. Response to letter to the editor	1
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark	1
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore	1
Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study	1
The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer	1
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	1
Design and testing of a health economic Markov model for treatment of anorexia nervosa	1
Cost-consequence analysis of diagnosis and early treatment of acquired thrombotic thrombocytopenic purpura in Colombia	1
Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience	1
A systematic review of cost-effectiveness analyses across the acute kidney injury landscape	1
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial	1
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective	1
Review of economic modeling evidence from NICE appraisals of rare disease treatments for spinal muscular atrophy	1
Pharmacoeconomics of obesity in China: a scoping review	1
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review	1
Correction	1
Implementing a Managed Entry Agreement Framework in Cyprus	1
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective	1
How should we measure the use of social care and informal care?	1
Use of prescription drug samples in the US and implications for pharmacoepidemiologic research: a systematic search of the literature	1
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	1
Technologies and decision-support tools for health systems management: a scoping review of features and use cases	1
Chronic inflammatory demyelinating polyneuropathy in Spain: a retrospective analysis of hospital incidence and medical costs	1
Perspectives in prospective comparative economic evaluations: a systematic review	1
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder	1
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	1
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events	1
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?	1
Performance-based risk-sharing agreements in renal care: current experience and future prospects	1
A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population	1
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention	1
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	1
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China	1
Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies	1
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country	1
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)	1
Cost effectiveness of hepatitis C direct acting agents	1
An update on the economic burden of type 2 diabetes mellitus in China	1
Use of the incremental cost-effectiveness ratio for decision-making policies—what is the problem? A perspective paper	1
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Sing	1
Valuing quality of life for economic evaluations in cancer: navigating multiple methods	1
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore	1
Correction	1
Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal	1
Monetary valuation of one year in full capability and health based on demographics, health status, income and well-being	1
Diabetes disparities in diabetes health care access and outcomes during the COVID-19 pandemic in the United States	1
Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China	1
Economic burden associated with stroke in India: insights from national sample survey 2017-18	1
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	1
A scoping review on patient heterogeneity in economic evaluations of precision medicine based on basket trials	1
Correction	1
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis	1
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia	1
An exploratory cost-effectiveness analysis of a novel tissue valve compared with mechanical valves for surgical aortic valve replacement in subgroups of people aged 55–64 and 65+ with aortic stenosis	1
HTA challenges for appraising rare disease interventions viewed through the lens of an institutional multidimensional value framework	1